61622-34-2

61622-34-2 structure
61622-34-2 structure
  • Name: Cefotiam
  • Chemical Name: cefotiam
  • CAS Number: 61622-34-2
  • Molecular Formula: C18H23N9O4S3
  • Molecular Weight: 525.628
  • Catalog: API Antibiotics Cephalosporin
  • Create Date: 2018-02-05 08:00:00
  • Modify Date: 2025-08-23 13:39:23
  • Cefotiam is a parenteral second-generation cephalosporin antibiotic. Cefotiam has broad-spectrum activity against gram-positive and gram-negative bacterias .Cefotiam has effective in preventing infection following a wide range of urologic surgeries[1][2][3].

Name cefotiam
Synonyms 7-[2-(2-aminothiazol-4-yl)acetamido]-3-[1-(2-N,N-dimethylaminoethyl)-tetrazol-5-yl]thiomethyl-3-cephem-4-carboxylic acid
MFCD00865087
CEFOTIAM HYDROCHLORIDE
Cefotiam (INN)
(6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)acetyl]amino]-3-[[1-[2-(dimethylamino)ethyl]tetrazol-5-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Haloapor
(6R)-7t-[2-(2-amino-thiazol-4-yl)-acetylamino]-3-[1-(2-dimethylamino-ethyl)-1H-tetrazol-5-ylsulfanylmethyl]-8-oxo-(6rH)-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Ceradolan
Cefotiamum [INN-Latin]
Ceradon
Cefotiamum
Description Cefotiam is a parenteral second-generation cephalosporin antibiotic. Cefotiam has broad-spectrum activity against gram-positive and gram-negative bacterias .Cefotiam has effective in preventing infection following a wide range of urologic surgeries[1][2][3].
Related Catalog
Target

MIC: 1.56 μg/mL (bacterial)

In Vitro Cefotiam (0.78-1.65 ug/mL, 4-8 h) has great antibacterial activity with the MIC value of 1.56 μg/mL against P. mirabilis IFO 3849[1]. Cell Viability Assay[1] Cell Line: P. mirabilis IFO 3849 Concentration: 0.78-1.65 ug / mL Incubation Time: 4-8 h Result: Showed great antibacterial activity
In Vivo Cefotiam (50-200mg/kg; Subcutaneous; twice a day for 5 days) can cure urinary tract infection with P. mirabilis in mice in appropriate doses for a sufficient length of the time[2]. Animal Model: Female CF1/b mice[2] Dosage: 50-200mg/kg Administration: Cefotiam (Subcutaneous; twice a day for 5 days). Result: Treated the experimental urinary tract infections.
References

[1]. Yumi Hashiguchi, et al. Clinical evaluation of cefotiam in the treatment of bacteremia caused by Escherichia coli, Klebsiella species, and Proteus mirabilis: A retrospective study. J Infect Chemother. 2020 Nov;26(11):1158-1163.

[2]. T Iwahi, et al. Comparative activities of cefotiam and cefazolin against urinary tract infections with Proteus mirabilis in mice. Antimicrob Agents Chemother

[3]. Kazuhiro Ishizaka, et al. Randomized prospective comparison of fosfomycin and cefotiam for prevention of postoperative infection following urological surgery. J Infect Chemother. 2007 Oct;13(5):324-31.

Density 1.8±0.1 g/cm3
Molecular Formula C18H23N9O4S3
Molecular Weight 525.628
Exact Mass 525.103516
PSA 251.30000
LogP 0.24
Index of Refraction 1.855
Water Solubility Soluble

CHEMICAL IDENTIFICATION

RTECS NUMBER :
XI0366000
CHEMICAL NAME :
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)acetyl) amino)-3-(((1-(2-(dimethylamino)ethyl)-1H-tetrazol-5- yl)thio)methyl)-8-oxo -, (6R-trans)-
CAS REGISTRY NUMBER :
61622-34-2
LAST UPDATED :
199506
DATA ITEMS CITED :
9
MOLECULAR FORMULA :
C18-H23-N9-O4-S3
MOLECULAR WEIGHT :
525.68
WISWESSER LINE NOTATION :
T46 ANV ES GUTJ HVQ CMV1- ET5N CSJ BZ& G1S- ET5NNNNJ A2N1&1

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
7800 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
JJANAX Japanese Journal of Antibiotics. (Japan Antibiotics Research Assoc., 2-20-8 Kamiosaki, Shinagawa-ku, Tokyo 141, Japan) V.21- 1968- Volume(issue)/page/year: 35,296,1982
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
3840 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
JJANAX Japanese Journal of Antibiotics. (Japan Antibiotics Research Assoc., 2-20-8 Kamiosaki, Shinagawa-ku, Tokyo 141, Japan) V.21- 1968- Volume(issue)/page/year: 35,296,1982 ** OTHER MULTIPLE DOSE TOXICITY DATA **
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
90 gm/kg/30D-I
TOXIC EFFECTS :
Kidney, Ureter, Bladder - changes in bladder weight Blood - normocytic anemia Skin and Appendages - dermatitis, other (after systemic exposure)
REFERENCE :
NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 27(Suppl 3),163,1979
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
182 gm/kg/26W-I
TOXIC EFFECTS :
Kidney, Ureter, Bladder - changes in bladder weight Skin and Appendages - dermatitis, other (after systemic exposure) Biochemical - Metabolism (Intermediary) - other proteins
REFERENCE :
NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 27(Suppl 3),163,1979
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
30 gm/kg/30D-I
TOXIC EFFECTS :
Gastrointestinal - changes in structure or function of salivary glands Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis)
REFERENCE :
NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 27(Suppl 3),163,1979
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
54600 mg/kg/26W-I
TOXIC EFFECTS :
Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis) Skin and Appendages - dermatitis, other (after systemic exposure) Skin and Appendages - hair
REFERENCE :
NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 27(Suppl 3),163,1979
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
30 gm/kg/30D-I
TOXIC EFFECTS :
Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis) Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol) Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - transaminases
REFERENCE :
NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 27(Suppl 3),163,1979
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Primate - monkey
DOSE/DURATION :
30 gm/kg/30D-I
TOXIC EFFECTS :
Liver - fatty liver degeneration Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis) Endocrine - changes in adrenal weight
REFERENCE :
NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 27(Suppl 3),163,1979
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
SPECIES OBSERVED :
Primate - monkey
DOSE/DURATION :
30 gm/kg/30D-I
TOXIC EFFECTS :
Liver - fatty liver degeneration Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis) Skin and Appendages - dermatitis, other (after systemic exposure)
REFERENCE :
NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 27(Suppl 3),163,1979
Hazard Codes Xi
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.